Here you will find the recommendations we have made about the use of individual medicines in Lancashire.

Oxycodone/Naloxone (Targinact®)

Brand: Targinact®
Indication: Restless Legs Syndrome
Disease category: Central nervous system
Commissioning responsibility: CCG
PbR excluded: No


Oxycodone hydrochloride/naloxone hydrochloride prolonged release tablets are not recommended for use as symptomatic treatment of patients with restless legs syndrome. Efficacy and safety data in support of Targinact® was not sufficient to allay concerns regarding;
· Safety issues and side effects associated with long term use of opioids
· The controlled drug status and potential for opioid abuse
· A lack of evidence for use beyond 1 year, uncertainty around the mechanism of action and potential for tolerance to develop when used to treat restless legs syndrome.

This colour classification is in agreement with the recommendations contained within both the NHS England and NHS Clinical Commissioners guidance document ‘Items which should not routinely be prescribed in primary care: Guidance for CCGs‘ published in November 2017.


LMMG recommendation: Black
Click here to find the definitions for the colour classifications

Reason for decision:  Not recommended for prescribing on the NHS in Lancashire

Supporting documents:

New Medicine Assessment - Targinact® for Restless Legs

Restless Legs Syndrome Guidelines (Version 1.1) (321.5 KiB)


Decisions of Lancashire local decision making groups:

NHS Blackburn With Darwen CCG and NHS East Lancashire CCG NHS Blackpool CCG NHS Chorley and South Ribble CCG and NHS Greater Preston CCG NHS Fylde and Wyre CCG NHS Morecambe Bay CCG NHS West Lancashire CCG